Currently, skin conditions are ranked as the 18th leading cause of global disability-adjusted life years (DALYs), which refer to the years lived with disability. Approximately one-fourth of the US population i.e. 84.5 million was affected by skin disease in 2013. Across the 7MM, the population suffering from acne vulgaris and atopic dermatitis stood at 128.9 million and 34.5 million, respectively, in 2017.
Global Markets Direct’s, ‘Wounds - Pipeline Review, H2 2017’, provides an overview of the Wounds pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Wounds, complete with analysis b...
Global Markets Direct’s, ‘Bullous Pemphigoid - Pipeline Review, H1 2018’, provides an overview of the Bullous Pemphigoid pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bullous ...
Global Markets Direct’s, ‘Alopecia - Pipeline Review, H2 2018’, provides an overview of the Alopecia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Alopecia, complete with anal...
Global Markets Direct’s, ‘Burns - Pipeline Review, H2 2018’, provides an overview of the Burns pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by s...
Global Markets Direct’s, ‘Pruritus - Pipeline Review, H2 2018’, provides an overview of the Pruritus pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pruritus, complete with anal...
Global Markets Direct’s, ‘Scar - Pipeline Review, H2 2018’, provides an overview of the Scar pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Scar, complete with analysis by stag...